Tianjin Medical University Cancer Institute and Hospital: clinical-trial pipeline
Tianjin Medical University Cancer Institute and Hospital is the sponsor of 490 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 233 are not yet finished and 22 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials233
Phase 2/3 and 337
Countries3
New in 90 days22
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 262 |
| Not applicable | 146 |
| Phase 3 | 25 |
| Phase 1 | 23 |
| Phase 2/3 | 12 |
| Phase 1/2 | 11 |
| Phase 4 | 11 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 215 |
| Not yet recruiting | 109 |
| Recruiting | 109 |
| Completed | 37 |
| Active, not recruiting | 15 |
| Withdrawn or not authorised | 3 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 421 |
| Gastroenterology and liver | 104 |
| Nephrology and urology | 13 |
| Women's health and obstetrics | 11 |
| Metabolic and endocrine (diabetes, obesity) | 10 |
| Cardiovascular | 6 |
| Neurology | 6 |
| Rare and genetic diseases | 6 |
| Respiratory | 6 |
| Immunology and rheumatology | 5 |
| Infectious disease and vaccines | 4 |
| Musculoskeletal | 3 |
Countries
| Country | Trials |
|---|---|
| China | 394 |
| Germany | 1 |
| United States | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | Effect of Low-Dose Esketamine Combined With Dexmedetomidine on the Incidence of Chronic P… |
| 2026-10-08 | New trial posted | Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Child… |
| 2026-10-02 | New trial posted | Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line T… |
| 2026-09-29 | New trial posted | FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Adv… |
| 2026-09-29 | New trial posted | Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC |
| 2026-09-24 | New trial posted | Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular C… |
| 2026-09-21 | New trial posted | Hypofractionated Radiotherapy After Breast Reconstruction for Breast Cancer |
| 2026-09-18 | New trial posted | Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer |
| 2026-09-17 | New trial posted | Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Pat… |
| 2026-09-14 | New trial posted | Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer |
| 2026-09-14 | New trial posted | SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant… |
| 2026-09-14 | New trial posted | Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery | Phase 3 | Recruiting | China |
| NCT06853678 | Second-line Immunotherapy for ES-SCLC | Not applicable | Recruiting | China |
| NCT06495515 | Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer | Phase 2 | Recruiting | China |
| NCT07302841 | Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer | Phase 4 | Not yet recruiting | |
| NCT07584018 | The DoHAICs Study Expansion Phase | Phase 2 | Not yet recruiting | |
| NCT07031700 | A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r… | Phase 2 | Not yet recruiting | |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | Phase 2 | Recruiting | China |
| NCT06454435 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chem… | Phase 2 | Not yet recruiting | China |
| NCT06867432 | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoin… | Phase 2 | Not yet recruiting | |
| NCT07776821 | An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Che… | Phase 4 | Recruiting | China |
| NCT07254416 | A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients | Phase 4 | Not yet recruiting | |
| NCT06363734 | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell L… | Phase 2 | Recruiting | China |
| NCT06914037 | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies | Phase 1 | Recruiting | China |
| NCT06814158 | Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer | Phase 2 | Not yet recruiting | China |
| NCT06704555 | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | Phase 2 | Recruiting | China |
| NCT07246317 | Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Adv… | Phase 2 | Not yet recruiting | China |
| NCT06954558 | A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor | Phase 1 | Recruiting | China |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induc… | Phase 3 | Recruiting | China |
| NCT05685550 | Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatmen… | Phase 2 | Active, not recruiting | China |
| NCT07622381 | Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer Surgery | Not applicable | Recruiting | China |
| NCT07351903 | A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment… | Phase 1 | Recruiting | China |
| NCT07281157 | Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Recta… | Phase 2 | Recruiting | China |
| NCT06717009 | A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Su… | Not applicable | Not yet recruiting | China |
| NCT07609641 | Surgical Total Clearance Versus Extrahepatic Bile Duct Preservation for Biliary Tract Malignancies: A Single-… | Not applicable | Recruiting | China |
| NCT06489197 | AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma P… | Phase 2 | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Tianjin Medical University Cancer Institute and Hospital clinical trials: 233 open, 37 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/tianjin-medical-university-cancer-institute-and-hospital/, data as of 2026-10-25.